Item 1(a). | Name of Issuer: |
Verrica Pharmaceuticals, Inc. (the “Issuer”)
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
44 West Gay Street, Suite 400
West Chester, PA 19380
Item 2(a). | Names of Persons Filing: |
The names of the persons filing this report (collectively, the “Reporting Persons”) are:
Perceptive Advisors LLC (“Perceptive Advisors”);
Joseph Edelman (“Mr. Edelman”); and
Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)
Item 2(b). | Address of Principal Business Office or, if None, Residence: |
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor
New York, NY 10003
Perceptive Advisors is a Delaware limited liability company;
Mr. Edelman is a United States citizen; and
The Master Fund is a Cayman Islands corporation
Item 2(d). | Title of Class of Securities: |
Common Stock, $0.0001 par value per share (“Common Stock”)
92511W108
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 90,564,840 outstanding shares of Common Stock, as reported by the Issuer in its prospectus supplemented filed with the Securities and Exchange Commission on November 21, 2024 and assumes the exercise of Pre-Funded Warrants held by the Reporting Persons for 1,481,481 shares of Common Stock.